Literature DB >> 6296967

Comparative pharmacokinetics of moxalactam, cefoperazone, and cefotaxime in normal volunteers.

H C Standiford, G L Drusano, W B McNamee, B Tatem, P A Ryan, S C Schimpff.   

Abstract

The pharmacokinetic parameters of moxalactam were compared with those of cefoperazone and cefotaxime in normal volunteers in a crossover manner. Following 30-min intravenous infusions of 2 g of each of the three antibiotics, serum levels at 1 hr were slightly lower for moxalactam (88 micrograms/ml) than for cefoperazone (112 micrograms/ml) but more than three times those obtained for cefotaxime (29 micrograms/ml). By 8 hr, levels of moxalactam (9.2 micrograms/ml) were slightly higher than those of cefoperazone (6.5 micrograms/ml), and levels of cefotaxime in serum were unmeasurable (less than 1 micrograms/ml). These values reflect differences in half lives of the three agents. Peak serum levels following intramuscular injection and serum levels during constant intravenous infusion were similar for moxalactam and cefoperazone because of counterbalancing differences in the apparent volume of distribution and rates of elimination of the two antibiotics. Serum levels of cefotaxime were much lower than those of the other two antibiotics primarily because of the rapid elimination of cefotaxime from the body. The kidney was the major route of excretion of moxalactam, whereas extrarenal mechanisms were more important for elimination of cefoperazone. These differences in pharmacokinetics may have significant implications for the clinical use of these new antibiotics.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6296967     DOI: 10.1093/clinids/4.supplement_3.s585

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  8 in total

1.  Correlation of predicted serum bactericidal activities and values measured in volunteers.

Authors:  G Drusano; H Standiford; P Ryan; W McNamee; B Tatem; S Schimpff
Journal:  Eur J Clin Microbiol       Date:  1986-02       Impact factor: 3.267

2.  Pharmacokinetics of cefoperazone in the parturient.

Authors:  B Gonik; S Feldman; L K Pickering; C G Doughtie
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

Review 3.  Technical aspects and clinical correlations of the serum bactericidal test.

Authors:  H C Standiford; B A Tatem
Journal:  Eur J Clin Microbiol       Date:  1986-02       Impact factor: 3.267

4.  Moxalactam and piperacillin: a study of in vitro characteristics and pharmacokinetics in cancer patients.

Authors:  G L Drusano; C de Jongh; K Newman; J Joshi; R Wharton; M R Moody; S C Schimpff
Journal:  Infection       Date:  1985 Jan-Feb       Impact factor: 3.553

5.  Assessment of serum bactericidal activity after administration of cefoperazone, cefotaxime, ceftizoxime, and moxalactam to healthy subjects.

Authors:  S L Barriere; D C Ozasa; J Mordenti
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

6.  Pharmacokinetics and dose proportionality of cefpimizole in normal humans after intramuscular administration.

Authors:  D B Lakings; E Novak; J M Friis; C M Lunan; L M Paxton
Journal:  Antimicrob Agents Chemother       Date:  1986-02       Impact factor: 5.191

Review 7.  Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; J A Romankiewicz; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-10       Impact factor: 9.546

8.  Comparison of the pharmacokinetics of ceftazidime and moxalactam and their microbiological correlates in volunteers.

Authors:  G L Drusano; H C Standiford; B Fitzpatrick; J Leslie; P Tangtatsawasdi; P Ryan; B Tatem; M R Moody; S C Schimpff
Journal:  Antimicrob Agents Chemother       Date:  1984-09       Impact factor: 5.191

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.